Journal of Clinical Endocrinology & Metabolism, Vol 70, 1616-1623, Copyright © 1990 by Endocrine Society

ARTICLES

Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin- like growth factor-I and metabolic indices

JO Jorgensen, N Moller, T Lauritzen and JS Christiansen
Second University Clinic of Internal Medicine, Aarhus Kommunehospital, Denmark.

The episodic and pulsatile nature of GH secretion in normal man is well established. Studies in hypophysectomized rats have indicated that pulsatile administration of GH is superior to continuous infusion in promoting growth, but similar studies have not yet been conducted in human subjects. We compared three different iv GH administration schedules in six GH-deficient patients. They were hospitalized three times for 44 h on three occasions, separated by at least 4 weeks without GH treatment. On each occasion they received 2 IU GH, administered iv as either 1) two boluses (at 2000 and 0200 h), 2) eight boluses (at 3-h intervals starting at 2000 h), or 3) a continuous (2000- 0200 h) infusion. Serum insulin-like growth factor-I (IGF-I) after eight boluses and that after continuous infusion were almost identical, with a steep increase reaching a peak at 2000-2400 h, followed by a steady decline. The total areas under the curve, expressed as mean levels (micrograms per L), were 147.6 +/- 11.8 (eight boluses) and 151.2 +/- 8.9 (infusion; P = NS). The change with time in IGF-I after the two-bolus regimen differed significantly from that in the other studies (P less than 0.001), displaying only a modest increase, as also reflected in a smaller area under the curve of serum IGF-I (125.3 +/- 8.7 micrograms/L; P less than 0.05). No differences in blood glucose, serum insulin, or plasma glucagon were observed when comparing the three studies. Both blood glucose and serum insulin tended to be elevated during the second night of each study. Almost identical fluctuations were recorded in lipid intermediates in the three studies, with nightly elevations being more pronounced on the first night. Alanine and lactate exhibited nearly identical patterns in the three studies and were characterized by low nocturnal levels. These data indicate that small but frequent iv boluses and continuous infusion of GH are equally effective in generating an increase in IGF-I in GH- deficient patients, whereas the same amount of GH given as two large boluses results in a significantly smaller increase in IGF-I. This could mean that a prolongation of the period during which serum GH is above zero in GH-treated subjects is just as essential as pulsatility for the growth-promoting effects of the hormone.

This article has been cited by other articles:

				D. F. MURESANU and H. S. SHARMA Chronic Hypertension Aggravates Heat Stress Induced Cognitive Dysfunction and Brain Pathology: An Experimental Study in the Rat, Using Growth Hormone Therapy for Possible Neuroprotection Ann. N.Y. Acad. Sci., December 1, 2007; 1122(1): 1 - 22. [Abstract] [Full Text] [PDF]

				A. P. Tuckow, K. R. Rarick, W. J. Kraemer, J. O. Marx, W. C. Hymer, and B. C. Nindl Nocturnal growth hormone secretory dynamics are altered after resistance exercise: deconvolution analysis of 12-hour immunofunctional and immunoreactive isoforms Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1749 - R1755. [Abstract] [Full Text] [PDF]

				T. Yonezawa, K. Mogi, J. Y. Li, R. Sako, K. Yamanouchi, and M. Nishihara Modulation of Growth Hormone Pulsatility by Sex Steroids in Female Goats Endocrinology, June 1, 2005; 146(6): 2736 - 2743. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers Endocrine Control of Body Composition in Infancy, Childhood, and Puberty Endocr. Rev., February 1, 2005; 26(1): 114 - 146. [Abstract] [Full Text] [PDF]

				L. S. Farhy and J. D. Veldhuis Putative GH pulse renewal: periventricular somatostatinergic control of an arcuate-nuclear somatostatin and GH-releasing hormone oscillator Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2004; 286(6): R1030 - R1042. [Abstract] [Full Text] [PDF]

				N. R. Biermasz, A. M. Pereira, M. Frolich, J. A. Romijn, J. D. Veldhuis, and F. Roelfsema Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E25 - E30. [Abstract] [Full Text]

				C. A. Jaffe, D. K. Turgeon, K. Lown, R. Demott-Friberg, and P. B. Watkins Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans Am J Physiol Endocrinol Metab, November 1, 2002; 283(5): E1008 - E1015. [Abstract] [Full Text] [PDF]

				D. M. Cook, B. M. K. Biller, M. L. Vance, A. R. Hoffman, L. S. Phillips, K. M. Ford, D. P. Benziger, A. Illeperuma, S. L. Blethen, K. M. Attie, et al. The Pharmacokinetic and Pharmacodynamic Characteristics of a Long-Acting Growth Hormone (GH) Preparation (Nutropin Depot) in GH-Deficient Adults J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4508 - 4514. [Abstract] [Full Text] [PDF]

				T. Laursen, C. H. Gravholt, L. Heickendorff, J. Drustrup, A.-M. Kappelgaard, J. O. L. Jørgensen, and J. S. Christiansen Long-Term Effects of Continuous Subcutaneous Infusion Versus Daily Subcutaneous Injections of Growth Hormone (GH) on the Insulin-Like Growth Factor System, Insulin Sensitivity, Body Composition, and Bone and Lipoprotein Metabolism in GH-Deficient Adults J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1222 - 1228. [Abstract] [Full Text]

				S. R. Peacey, A. A. Toogood, J. D. Veldhuis, M. O. Thorner, and S. M. Shalet The Relationship between 24-Hour Growth Hormone Secretion and Insulin-Like Growth Factor I in Patients with Successfully Treated Acromegaly: Impact of Surgery or Radiotherapy J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 259 - 266. [Abstract] [Full Text]

				T. Laursen, A. Flyvbjerg, J. O. L. Jørgensen, R. C. Baxter, and J. S. Christiansen Stimulation of the 150-Kilodalton Insulin-Like Growth Factor-Binding Protein-3 Ternary Complex by Continuous and Pulsatile Patterns of Growth Hormone (GH) Administration in GH-Deficient Patients J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4310 - 4314. [Abstract] [Full Text]

				D. M. Keenan and J. D. Veldhuis Explicating hypergonadotropism in postmenopausal women: a statistical model Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2000; 278(5): R1247 - R1257. [Abstract] [Full Text] [PDF]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				I. M. Chapman, M. L. Hartman, K. S. Pieper, E. H. Skiles, S. S. Pezzoli, R. L. Hintz, and M. O. Thorner Recovery of Growth Hormone Release from Suppression by Exogenous Insulin-Like Growth Factor I (IGF-I): Evidence for a Suppressive Action of Free Rather Than Bound IGF-I J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2836 - 2842. [Abstract] [Full Text]

				H. J. Lee, G. Riley, O. Johnson, J. L. Cleland, N. Kim, M. Charnis, L. Bailey, E. Duenas, A. Shahzamani, M. Marian, et al. J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1431 - 1439. [Abstract]

				G. Van den Berghe, F. de Zegher, J. D. Veldhuis, P. Wouters, M. Awouters, W. Verbruggen, M. Schetz, C. Verwaest, P. Lauwers, R. Bouillon, et al. The Somatotropic Axis in Critical Illness: Effect of Continuous Growth Hormone (GH)-Releasing Hormone and GH-Releasing Peptide-2 Infusion J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 590 - 599. [Abstract] [Full Text] [PDF]